TEVA Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

4.36B

+3.21%

0.649

-8.55%

4.01B

+3.02%

0.583

+12.12%

4.21B

+0.71%

0.651

-1.36%

Estimates Revision

The market is revising Upward the revenue expectations for Teva Pharmaceutical Industries Limited (TEVA) for FY2025, with the revenue forecasts being adjusted by 0.25% over the past three months. During the same period, the stock price has changed by 59.73%.

Revenue Estimates for FY2025

Revise Upward

+0.25%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+3.02%

In Past 3 Month

Stock Price

Go Up

+59.73%

In Past 3 Month

6 Analyst Rating

Wall Street analysts forecast TEVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TEVA is 29.25 USD with a low forecast of 28.00 USD and a high forecast of 32.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

28.00

Averages

29.25

High

32.00

Current: 0.000

Low

28.00

Averages

29.25

High

32.00

Truist

Buy

maintain

$32 -> $36

2026-01-07

New

Reason

Truist

Price Target

$32 -> $36

2026-01-07

New

maintain

Buy

Reason

Truist raised the firm's price target on Teva to $36 from $32 and keeps a Buy rating on the shares. The affordable medicines theme remains attractive heading into 2026, the analyst tells investors in a research note.

Jefferies

Buy

maintain

$29 -> $40

2026-01-06

New

Reason

Jefferies

Price Target

$29 -> $40

2026-01-06

New

maintain

Buy

Reason

Jefferies raised the firm's price target on Teva to $40 from $29 and keeps a Buy rating on the shares, which the analyst introduced as a top 2026 idea. The narrative should shift in 2026 and beyond with several pipeline catalysts, but key is convincing investors to ascribe a positive terminal value to reflect R&D productivity when historically none was given, says the analyst, who expects the R&D engine to "start bearing fruit in 2026."

Piper Sandler

Overweight

upgrade

$30 -> $40

2025-12-22

Reason

Piper Sandler

Price Target

$30 -> $40

2025-12-22

upgrade

Overweight

Reason

Piper Sandler raised the firm's price target on Teva to $40 from $30 and keeps an Overweight rating on the shares. The firm is also making an argument for further multiple expansion. Teva's peer group is evolving as the mix continues to shift towards novel brand assets. In other words, the larger cap biopharma group is becoming a more appropriate peer group for Teva, Piper argues. As the firm layers in contribution from TL1A-directed treatment duvakitug in inflammatory bowel disease, and considers that Teva is not staring down significant loss of exclusivity exposure, it believes an even richer multiple is in order.

Goldman Sachs

Buy

maintain

$31 -> $35

2025-12-18

Reason

Goldman Sachs

Price Target

$31 -> $35

2025-12-18

maintain

Buy

Reason

Goldman Sachs raised the firm's price target on Teva to $35 from $31 and keeps a Buy rating on the shares.

JPMorgan

Chris Schott

Overweight

upgrade

$28 -> $35

2025-12-16

Reason

JPMorgan

Chris Schott

Price Target

$28 -> $35

2025-12-16

upgrade

Overweight

Reason

JPMorgan analyst Chris Schott raised the firm's price target on Teva to $35 from $28 and keeps an Overweight rating on the shares. The firm upped 2027 estimates to reflect the Centers for Medicare and Medicaid Services Austedo announcement.

BofA

Buy

maintain

$29 -> $32

2025-12-09

Reason

BofA

Price Target

$29 -> $32

2025-12-09

maintain

Buy

Reason

BofA raised the firm's price target on Teva to $32 from $29 and keeps a Buy rating on the shares after having hosted fireside chats with management teams at the firm's CNS Therapeutics Conference.

Valuation Metrics

The current forward P/E ratio for Teva Pharmaceutical Industries Ltd (TEVA.N) is 11.97, compared to its 5-year average forward P/E of 4.80. For a more detailed relative valuation and DCF analysis to assess Teva Pharmaceutical Industries Ltd 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

4.80

Current PE

11.97

Overvalued PE

6.74

Undervalued PE

2.86

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

6.97

Current EV/EBITDA

10.09

Overvalued EV/EBITDA

7.64

Undervalued EV/EBITDA

6.30

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

0.88

Current PS

2.10

Overvalued PS

1.20

Undervalued PS

0.56

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

TEVA News & Events

Events Timeline

No data

News

1.0

01-05Globenewswire

Teva CEO Richard Francis to Present at J.P. Morgan Healthcare Conference on January 13

4.5

01-02NASDAQ.COM

EFA ETF Hits 52-Week High of $96.73, Low at $72.145

6.0

01-02Benzinga

Teva Pharmaceutical Upgraded to 'BB+' by S&P, Stock Rises 16% in a Month

People Also Watch

Frequently Asked Questions

What is Teva Pharmaceutical Industries Ltd (TEVA) stock price today?

The current price of TEVA is 32.01 USD — it has decreased -1.54 % in the last trading day.

What is Teva Pharmaceutical Industries Ltd (TEVA)'s business?

Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.

What is the price predicton of TEVA Stock?

What is Teva Pharmaceutical Industries Ltd (TEVA)'s revenue for the last quarter?

Teva Pharmaceutical Industries Ltd revenue for the last quarter amounts to 4.48B USD, increased 3.42 % YoY.

What is Teva Pharmaceutical Industries Ltd (TEVA)'s earnings per share (EPS) for the last quarter?

Teva Pharmaceutical Industries Ltd. EPS for the last quarter amounts to 0.37 USD, decreased -194.87 % YoY.

What changes have occurred in the market's expectations for Teva Pharmaceutical Industries Ltd (TEVA)'s fundamentals?

How many employees does Teva Pharmaceutical Industries Ltd (TEVA). have?

Teva Pharmaceutical Industries Ltd (TEVA) has 33892 emplpoyees as of January 10 2026.

What is Teva Pharmaceutical Industries Ltd (TEVA) market cap?

Today TEVA has the market capitalization of 36.72B USD.